Lilly colon cancer drug succeeds in late stage study

Sept 12 (Reuters) - Eli Lilly and Co said its colon cancer drug extended survival compared to a placebo, in a late stage trial.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.